-
1
-
-
0032810805
-
Guidelines for severe community-acquired pneumonia in the western world
-
Vegelin AL, Bissumbhar P, Joore JC, et al: Guidelines for severe community-acquired pneumonia in the western world. Neth J Med 1999; 55:110-117
-
(1999)
Neth J Med
, vol.55
, pp. 110-117
-
-
Vegelin, A.L.1
Bissumbhar, P.2
Joore, J.C.3
-
2
-
-
0001011923
-
Antimicrobial agents. the animoglycosides
-
Hardman JG, Gilman AG, Limbird LE (eds). New York, McGraw-Hill Co, 9th Ed, Chap 46
-
Chambers HF, Sande MA: Antimicrobial agents. the animoglycosides. Goodman and Gilman's The Pharmacological Basis of Therapeutics. Hardman JG, Gilman AG, Limbird LE (eds). New York, McGraw-Hill Co, 9th Ed, 1996, Chap 46, pp 1103-1117
-
(1996)
Goodman and Gilman's the Pharmacological Basis of Therapeutics
, pp. 1103-1117
-
-
Chambers, H.F.1
Sande, M.A.2
-
3
-
-
0025814950
-
Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients
-
Krcmery V Jr, Fuchsberger P, Gocar M, et al: Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients. Chemotherapy 1991; 37:287-291
-
(1991)
Chemotherapy
, vol.37
, pp. 287-291
-
-
Krcmery V., Jr.1
Fuchsberger, P.2
Gocar, M.3
-
5
-
-
0016780706
-
Nephrotoxicity of combined cephalosporin-gentamicin regimen
-
Cabanillas F, Burgos RC, Rodriguez C, et al: Nephrotoxicity of combined cephalosporin-gentamicin regimen. Arch Intern Med 1975; 135:850-852
-
(1975)
Arch Intern Med
, vol.135
, pp. 850-852
-
-
Cabanillas, F.1
Burgos, R.C.2
Rodriguez, C.3
-
6
-
-
0019791784
-
Antibiotic combination-associated nephrotoxicity in granulocytopenic patients with cancer
-
Wade JC, Schimpff SC, Wiernik PH: Antibiotic combination-associated nephrotoxicity in granulocytopenic patients with cancer. Arch Intern Med 1981; 141:1789-1793
-
(1981)
Arch Intern Med
, vol.141
, pp. 1789-1793
-
-
Wade, J.C.1
Schimpff, S.C.2
Wiernik, P.H.3
-
7
-
-
0027324684
-
Lung distribution and pharmacokinetics of aerosolized tobramycin
-
LeConte P, Potel G, Peltier P, et al: Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993; 147:1279-1282
-
(1993)
Am Rev Respir Dis
, vol.147
, pp. 1279-1282
-
-
LeConte, P.1
Potel, G.2
Peltier, P.3
-
8
-
-
0032968947
-
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
-
Burns JL, Van Dalfsen JM, Shawar RM, et al: Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190-1196
-
(1999)
J Infect Dis
, vol.179
, pp. 1190-1196
-
-
Burns, J.L.1
Van Dalfsen, J.M.2
Shawar, R.M.3
-
9
-
-
0027287651
-
Efficacy of aerosolized tobramycin in patients with cystic fibrosis
-
Ramsey BW, Dorkin HL, Eisenberg JD, et al: Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993; 328:1740-1746
-
(1993)
N Engl J Med
, vol.328
, pp. 1740-1746
-
-
Ramsey, B.W.1
Dorkin, H.L.2
Eisenberg, J.D.3
-
10
-
-
0024790626
-
Safety of aerosol tobramycin administration for three months to patients with cystic fibrosis
-
Smith AL, Ramsey BW, Hedges DL, et al: Safety of aerosol tobramycin administration for three months to patients with cystic fibrosis. Pediatr Pulmonol 1989; 7:265-271
-
(1989)
Pediatr Pulmonol
, vol.7
, pp. 265-271
-
-
Smith, A.L.1
Ramsey, B.W.2
Hedges, D.L.3
-
11
-
-
0024455373
-
The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonitis
-
McCall CY, Spruill WJ, Wade WE: The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonitis. Ther Drug Monit 1989; 11:692-695
-
(1989)
Ther Drug Monit
, vol.11
, pp. 692-695
-
-
McCall, C.Y.1
Spruill, W.J.2
Wade, W.E.3
|